Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benomyl is a systemic benzimidazole fungicide introduced in 1968 by DuPont, primarily used to control a wide range of fungal diseases in crops and ornamentals. Its fungicidal mechanism is based on disruption of tubulin polymerization, thereby inhibiting microtubule formation and arresting fungal cell division. Benomyl is moderately persistent and rapidly degrades to carbendazim (MBC), another fungicidal compound, after application. In addition to its intended effects, benomyl exposure can induce oxidative stress, apoptosis in neural cells, teratogenicity, reproductive and hepatic toxicity in mammals, and is classified as a possible carcinogen by regulatory agencies. Its use is restricted or banned in the US/EU due to these toxicity concerns, but remains common in developing countries[1][3][5][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on benomyl.